Key result
Patient-specific induced pluripotent stem cell-derived cardiomyocytes offer a breakthrough technology for modeling inherited arrhythmias and cardiomyopathies and testing drug compounds.
Human induced pluripotent stem cell-derived cardiomyocytes provide a valuable platform for modeling inherited cardiovascular diseases, overcoming physiological differences seen in animal models.
May support preclinical modeling of inherited arrhythmias; leaves open clinical translation pending prospective validation.
Fundamental studies of molecular and cellular mechanisms of cardiovascular disease pathogenesis are required to create more effective and safer methods of their therapy. The studies can be carried out only when model systems that fully recapitulate pathological phenotype seen in patients are used. Application of laboratory animals for cardiovascular disease modeling is limited because of physiological differences with humans. Since discovery of induced pluripotency generating induced pluripotent stem cells has become a breakthrough technology in human disease modeling. In this review, we discuss a progress that has been made in modeling inherited arrhythmias and cardiomyopathies, studying molecular mechanisms of the diseases, and searching for and testing drug compounds using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Bayzigitov et al. (2016) conducted a review in Inherited cardiovascular disease. Human induced pluripotent stem cell-derived cardiomyocytes was evaluated. Patient-specific induced pluripotent stem cell-derived cardiomyocytes offer a breakthrough technology for modeling inherited arrhythmias and cardiomyopathies and testing drug compounds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: